Human inducible nitric oxide synthase,iNOS ELISA KIT

Code CSB-E08148h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
nitric oxide synthase 2, inducible
Alternative Names
HEP-NOS ELISA Kit; Hepatocyte NOS ELISA Kit; HEPNOS ELISA Kit; inducible ELISA Kit; Inducible nitric oxide synthase ELISA Kit; Inducible NO synthase ELISA Kit; Inducible NOS ELISA Kit; iNOS ELISA Kit; MAC NOS ELISA Kit; Macrophage NOS ELISA Kit; Nitric oxide synthase 2 inducible ELISA Kit; Nitric oxide synthase 2 inducible macrophage ELISA Kit; nitric oxide synthase 2A (inducible, hepatocytes) ELISA Kit; Nitric oxide synthase ELISA Kit; Nitric oxide synthase inducible ELISA Kit; nitric oxide synthase, macrophage ELISA Kit; NOS 2 ELISA Kit; NOS ELISA Kit; Nos II ELISA Kit; NOS type II ELISA Kit; nos2 ELISA Kit; NOS2_HUMAN ELISA Kit; NOS2A ELISA Kit; NOS2A, Inducible, Hepatocyte ELISA Kit; Peptidyl-cysteine S-nitrosylase NOS2 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.9 IU/mL-60 IU/mL
0.225 IU/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human iNOS in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %93
Range %89-95
1:2Average %103
Range %99-105
1:4Average %94
Range %90-97
1:8Average %99
Range %95-101
The recovery of human iNOS spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9592-97
EDTA plasma (n=4)9692-98
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
602.519 2.499 2.509 2.378
301.934 1.876 1.905 1.774
151.277 1.281 1.279 1.148
7.50.695 0.683 0.689 0.558
3.750.442 0.434 0.438 0.307
1.80.317 0.302 0.310 0.179
0.90.218 0.225 0.222 0.091
00.133 0.129 0.131  
Materials provided
  • A micro ELISA plate --The 96-well plate has been pre-coated with an anti-human NOS2 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard --Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled NOS2 antibody (100 x concentrate) (120 μl/bottle) --Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) --Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibody Diluent (15 ml/bottle) --Dilute the high concentration Biotin-antibody to an appropriate working solution.
  • One vial HRP-avidin Diluent (15 ml/bottle) --Dilute the high concentration HRP-avidin solution to an appropriate solution.
  • One vial Sample Diluent (50 ml/bottle)--Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) --- Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) --Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) --Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human NOS2 ELISA Kit was designed for the quantitative measurement of Human NOS2 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.9 IU/mL-60 IU/mL and the sensitivity is 0.225 IU/mL .


Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM. Involved in inflammation, enhances the synthesis of proinflammatory mediators such as IL6 and IL8.
Gene References into Functions
  1. These findings link iNOS to Notch1 signaling in CD24(+)CD133(+) LCSCs through the activation of TACE/ADAM17. PMID: 30297396
  2. the present findings were the first to show that KLF5 expression and nitration by iNOS-mediated peroxynitrite are necessary for the induction of TNF-alpha and IL-1beta expression in VSMCs of diabetic vascular tissues. PMID: 28711598
  3. iNOS microsatellite polymorphism may contribute to the genetic background of atrial fibrillation in Chinese-Taiwanese patients. PMID: 28205526
  4. High expression of iNOS and STAT3 in cells transfected with miR-34a mimic further validated it. PMID: 30021364
  5. ur findings endorse polymorphic regulation of iNOS expression, altered oxidant-antioxidant components and evidences of risk association as the hallmark of malaria pathogenesis. iNOS/NO may serve as potential diagnostic marker in assessing clinical malaria. PMID: 29268202
  6. NOS2A_ (CCTTT)n gene variations may influence inflammatory bowel disease susceptibility in the Moroccan population. PMID: 29307990
  7. The results indicated that the expression levels of interleukin6 and inducible nitric oxide synthase (iNOS) were decreased, whereas collagen expression and deposition were increased in ketaminetreated SMCs. Conversely, treatment with CTX restored the expression of iNOS, which may prevent or limit oxidative damage PMID: 29207018
  8. The present study demonstrated that iNOS C150T polymorphism did not show significant association with metabolic syndrome. PMID: 29637536
  9. KLF4 activated the transcription activity of iNOS promoter in MH7A cells stimulated by TNF-alpha. This study indicates that KLF4 is important for regulating the expression of iNOS by TNF-alpha in human synoviocytes. PMID: 28744810
  10. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. PMID: 29087320
  11. NOS2 T allele of rs2297514 significantly increased the risk of a non-union during the fracture healing process by 38% compared to the C allele. Further stratification analyses conducted for this SNP using data from subgroups classified by different sites of fracture indicated that significance could only be observed in the tibial diaphysis subgroup. PMID: 29518099
  12. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients PMID: 29522543
  13. PEDF protects human glomerular mesangial cells from diabetes-derived oxidative stress via NOXO1- iNOS suppression. PMID: 28944893
  14. The studies established a potential link between leptin and adipocyte insulin responsiveness in an NOS2 dependent manner. PMID: 28739528
  15. Collectively, our results demonstrated sanggenon C induced apoptosis of colon cancer cells by increased reactive oxygen species generation and decreased nitric oxide production, which is associated with inhibition of inducible nitric oxide synthase expression(iNOS) and activation of mitochondrial apoptosis pathway. PMID: 28849234
  16. Data show that infecting unencapsulated E. faecalis cps2 is a stronger stimulator for toll like receptor 2 (TLR2) and interleukin-1beta (IL-1beta) mRNAs, but not for inducible nitric oxide synthase (iNOS) mRNA. PMID: 28800779
  17. Results show that NOS2A CpG(+5099) was associated with increased FeNO and that the magnitude of association between black carbon exposure and demethylation of NOS2A CpG(+5099) measured 5 days later appeared to be greater among seroatopic children, especially those sensitized to cockroach allergens. PMID: 28588744
  18. Results support that iNOS polymorphisms not only are associated with Henoch-Schonlein purpura (HSP) risk but also strongly contribute to the genetic basis of individual differences in the progression of HSP to nephritis among Chinese Han children. PMID: 28593405
  19. This study investigates whether the -1026(A>C)(rs2779249) and +2087(A>G)(2297518) polymorphisms in the NOS2 gene are associated with chronic periodontitis (CP). The analysis demonstrated, after correction for multiple comparisons, that only the female gender was significantly associated with CP. PMID: 28617311
  20. The study summarizes and discuss NOS2 expression in tumor-associated leukocytes and elucidate nitric oxide signaling during tumor initiation, tumor progression. [review] PMID: 27397579
  21. Studies show that majority of patients with gastrointestinal cancer have elevated expression of NOS2. Furthermore, NOS/NO levels are often associated with increased metastasis, leading to poor patient prognosis. The association of elevated NOS2 expression with cancers arising due to bacterial, viral, and fungal infections suggests an important relationship of tumor immune response and chronic inflammation. [review] PMID: 27494631
  22. Results show that overexpression of iNOS is associated with aggressive phenotype and poor survival outcome in ovarian cancer patients, and indicates that iNOS/NO play a dual role of in tumor glycolysis and progression PMID: 28380434
  23. Positive rates of iNOS in cervical tissues were 72.1%, 28.2%, and 3.1% in the -HPV-positive patients with cervical cancer (CC group), HR-HPV group, and controls, respectively (P < 0.05). Levels of TLR3, TLR4, TLR7, TLR8, NF-kappaB p65, and iNOS in cervical epithelial cells were higher in CC group than in other groups. PMID: 28626766
  24. Studies show that NOS2 is highly expressed in ovarian and prostate tumors and provide evidence for its role in the development of aggressive ovarian cancer and progression of prostate cancer. [review] PMID: 28326819
  25. Studies elucidate the nitric oxide-driven pathways which implicate NOS2 as a key driver of breast cancer disease progression. [review] PMID: 27464521
  26. Although haplotype analysis revealed that no NOS2 haplotype was associated with leprosy susceptibility/resistance with statistical significance, GTG haplotype was noted to be more frequent in healthy controls. PMID: 28315742
  27. The results shed light on the potential relevance of NOS2 as a prognostic factor for glioma malignancy and recurrence. PMID: 28424427
  28. These data revealed that human endogenous retrovirus W env might contribute to increase nitric oxide production and microglial migration ability in neuropsychological disorders by regulating the expression of inducible nitric oxide synthase. PMID: 28656540
  29. Since RP11-19P22.6-001 acts in cis to regulate nitric oxide synthase 2 (NOS2), we also analyzed NOS2 expression and its correlation with gastric cancer. The combined use of lncRNAs and their target genes may be a promising method to increase the diagnostic value of lncRNAs in cancer. PMID: 28128738
  30. expression elevated in preeclampsia placentas PMID: 27030287
  31. Inducible nitric oxide synthase is able to regulate many cytokines in mast cells involved in the development of irritable bowel syndrome. PMID: 26940641
  32. Role of a conserved tyrosine residue in the FMN-Heme interdomain electron transfer in inducible nitric oxide synthase. PMID: 27633182
  33. expression highly associated with hallmarks of psoriasis such as hypogranulosis and neutrophils, but negatively associated with eosinophils and spongiosis which are characteristics of eczema PMID: 27193975
  34. Bone marrow mesenchymal stromal cells induce the rapid differentiation of CD11b+ myeloid cells from bone marrow progenitors, and such an activity requires the expression of nitric oxide synthase-2. PMID: 28183849
  35. Studied iNOS(inducible nitric oxide synthase) activation thru mPGES-1 (microsomal prostaglandin E synthase-1) signaling driven by EGFR (EGF receptor) in cancer progression models. PMID: 28257996
  36. Higher expression of inducible nitric oxide synthase (NOS2) is associated with poor survival in patients with pancreatic ductal adenocarcinoma (PDAC). PMID: 27367029
  37. The Oncogenic Properties Of The Redox Inflammatory Protein Inducible Nitric Oxide Synthase In ER(-) Breast Cancer. PMID: 28162269
  38. Exploration into the mechanisms of the cGMP-mediated protection identified a role for the iNOS/NO/cGMP pathway in the activation of ADAM17 (TACE), which is a sheddase that cleaves a number of cell surface receptors including TNF receptor type 1 (TNFR1). PMID: 28162283
  39. results suggest that NOS2 polymorphisms may influence the risk of aggressive prostate cancer and that these polymorphisms could have an impact on disease pathogenesis, possibly by affecting intracellular nitric oxide levels. PMID: 28162285
  40. no significant difference in frequency of NOS2-1659C/T polymorphism was observed between patients and controls. None of the studied SNPs were associated with erosive disease, seropositivity or extra-articular manifestations. The -277A/G and -1026 G/T promoter polymorphisms in iNOS may confer susceptibility to rheumatoid arthritis (RA). in South Indian Tamils. PMID: 28374504
  41. This is the first reported evidence for NO-enhanced bystander aggressiveness in the context of PDT. In the clinical setting, such effects could be averted through pharmacologic use of iNOS inhibitors as non-ionizing photodynamic therapy adjuvants PMID: 27884704
  42. This increase was inhibited in the presence of the nonspecific iNOS inhibitor aminoguanidine (AG). PMID: 27247425
  43. our study shows that the expression of iNOS is increased in both central airways and the alveolar parenchyma, but not in BAL cells, in uncontrolled asthmatics as compared to controlled asthmatics and healthy controls. PMID: 27647044
  44. We found that lowering the glucose concentration increased expression of genes coding for inducible nitric oxide syntheas, NOS2 and NOS2A resulting in enhanced production of nitric oxide PMID: 28157664
  45. Downregulation of inducible NO synthetase (iNOS) resulted in downregulation of heme oxygenase 1 (HO-1), and, conversely, upregulation of iNOS enhanced HO-1 activity. PMID: 27752990
  46. expression in synovial subintima was significantly higher in early than in advanced osteoarthritis PMID: 27958655
  47. ATM-reactive oxygen species-iNOS axis regulates nitric oxide mediated cellular senescence. PMID: 27845209
  48. The risk of developing chronic pancreatitis is not increased by the presence of the iNOS-2087A>G polymorphism. PMID: 28125406
  49. NOS2 rs2779248, NOS2 rs1137933, and NOS3 rs3918188 genetic polymorphisms are potentially related to the susceptibility to type 2 diabetes mellitus (T2DM), and the rs1800783 polymorphism might be considered as genetic risk factors for diabetic nephropathy. PMID: 27192959
  50. Patients with Marfan syndrome showed elevated NOS2 and decreased ADAMTS1 protein levels in the aorta. PMID: 28067899

Show More

Hide All

Subcellular Location
Cytoplasm, cytosol.
Protein Families
NOS family
Tissue Specificity
Expressed in the liver, retina, bone cells and airway epithelial cells of the lung. Not expressed in the platelets.
Database Links

HGNC: 7873

OMIM: 163730

KEGG: hsa:4843

STRING: 9606.ENSP00000327251

UniGene: Hs.709191

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1